Clinical Trials for Non-Small Cell Lung Cancer

Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adult patients with advanced solid tumors, including NSCLC, who have progressed after anti-PD-1/PD-L1 therapy to evaluate MEM-288, an oncolytic adenovirus with immunostimulatory properties, alone and in combination with the PD-1 inhibitor nivolumab.

ClinicalTrials.gov ID: NCT05076760

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates LY3537982, an oral KRAS G12C inhibitor, in patients with advanced solid tumors that harbor the KRAS G12C mutation, including NSCLC and CRC, and involves combination therapies with pembrolizumab, cetuximab, pemetrexed, and platinum agents. Eligible patients must have measurable disease, ECOG status 0 or 1, adequate organ function, and prior resistance or intolerance to standard treatments.

ClinicalTrials.gov ID: NCT04956640

Phase II Trial of the Addition of Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to First Line Osimertinib in Oligoprogressive EGFR Positive Non-Small Cell Lung Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the effectiveness of adding biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy (SBRT) to first-line osimertinib treatment in patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) showing oligoprogressive disease. It focuses on disease control rates at 6 months and overall efficacy and safety, with osimertinib acting as a third-generation EGFR tyrosine kinase inhibitor.

ClinicalTrials.gov ID: NCT06014827

A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets adults with stage IV NSCLC involving liver metastases, excluding those with EGFR or BRAF mutations and prior liver radiation, to evaluate the impact of adding liver stereotactic ablative radiotherapy (L-SABR) to a standard regimen of anti-PD-(L)1 based immunotherapy and optional platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT05657873

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets adult patients with advanced solid malignancies and evaluates the safety and efficacy of CRX100, an investigational immunotherapy combining autologous T cells and oncolytic vaccinia virus, as monotherapy and in combination with Pembrolizumab.

ClinicalTrials.gov ID: NCT04282044

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the efficacy and safety of pembrolizumab alone versus pembrolizumab combined with chemotherapy (carboplatin, pemetrexed, nab-paclitaxel, or paclitaxel) in vulnerable adults aged 70 and older with advanced NSCLC (stage IIIB-IV) and a PD-L1 TPS of 1-49% who are treatment-naïve for metastatic disease.

ClinicalTrials.gov ID: NCT06096844

A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls patients newly diagnosed with Stage IV NSCLC with PD-L1 expression ≥1%, testing whether immunotherapy with PD-1 inhibitor nivolumab and CTLA-4 inhibitor ipilimumab, guided by ctDNA response, can be effective alone or if it necessitates the addition of chemotherapy with Carboplatin and Paclitaxel or Pemetrexed.

ClinicalTrials.gov ID: NCT05715229

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets adult patients with KRAS G12C mutant non-small cell lung cancer, evaluating the safety and efficacy of the combination of avutometinib, a dual RAF/MEK inhibitor, with sotorasib, with or without defactinib, for those with or without prior exposure to KRAS G12C inhibitors.

ClinicalTrials.gov ID: NCT05074810

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients with advanced/metastatic solid tumors, particularly those with non-small cell lung cancer (NSCLC) harboring EGFR mutations and/or cMET aberrations, who have exhausted standard treatments. It investigates EMB-01, a bispecific antibody targeting EGFR and cMET receptors, using EpimAb's FIT-Ig® platform, with weekly administrations in 28-day cycles.

ClinicalTrials.gov ID: NCT03797391

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adult patients with advanced HER2-positive or HER2-expressing solid tumors who are refractory to standard treatment, targeting HER2 with the novel antibody-drug conjugate DB-1303/BNT323, which combines a humanized anti-HER2 IgG1 monoclonal antibody and a DNA topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT05150691